PBAC's latest decision on Tafasitamab: Recommended with restriction (2025). Considered for Treatment of adults with relapsed or refractory follicular lymphoma who have had at least 1 prior systemic anti-CD20 therapy, in combination with lenalidomide and rituximab.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Redacted
commercial-in-confidence
Submissions
1
first 2025
Submissions
1
2025 → 2025
Eligible population
Adults with relapsed or refractory follicular lymphoma who have had at least 1 prior systemic anti-CD20 therapy
Therapy area
Haematology
Line of therapy
Second-line
Evidence base
RCT
Primary endpoint
PFS
Key trials
inMIND
Comparator
rituximab-based chemotherapy (R-CHOP)
Economic model
CUA
ICER note
ICER value is redacted; published price and effective price shown as '&&&&' in the document.